Episode Details
Back to Episodes
Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce
Description
FDA approves J&J's Icotyde — the first oral IL-23Rpeptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead cancer program zelenectide, Sandoz and Samsung Bioepis partner on five biosimilars, and Eli Lilly slides 7% on a rare HSBCdowngrade.
Follow us at: https://thepharmacloseout.com
pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Icotyde,icotrokinra, Johnson & Johnson, Protagonist Therapeutics, psoriasis, FDA approval, Bicycle Therapeutics, zelenectide, Padcev, Sandoz, Samsung Bioepis, biosimilar, Entyvio, Eli Lilly, HSBC, GLP-1, obesity, Crossbow Therapeutics,TerraPower, radiopharmaceutical, actinium-225, GSK, linerixibat, RMAT, Pfizer, Lilly, J&J, AbbVie, Takeda